Free Trial
→ From the man who predicted 2008 crash… (From Porter & Company) (Ad)tc pixel
NASDAQ:IMRX

Immuneering Q1 2026 Earnings Report

Immuneering logo
$5.38 +0.20 (+3.86%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$5.38 0.00 (0.00%)
As of 07:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immuneering EPS Results

Actual EPS
N/A
Consensus EPS
-$0.30
Beat/Miss
N/A
One Year Ago EPS
N/A

Immuneering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immuneering Announcement Details

Quarter
Q1 2026
Date
5/14/2026
Time
Before Market Opens
Conference Call Date
Monday, May 18, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Immuneering Earnings Headlines

Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Moderate Buy" by Brokerages
May 12 at 2:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30772724
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely
May 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/were-hopeful-immuneering-nasdaq-imrx-145323224.html
What is “gold skimming”?
Former $900 million hedge fund manager Larry Benedict has developed a strategy he calls Gold Skimming - a way to target cash payouts from gold markets without buying a single ounce, mining stock, or ETF. With a reported 73% win rate across 19 trades and potential payouts of $2,975, $3,781, and $6,786 in a single day, Benedict has put together a free step-by-step walkthrough showing how it works whether gold climbs or pulls back.tc pixel
May 14 at 1:00 AM  |  Brownstone Research (Ad)
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and McKesson (MCK)
April 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MCK/pressreleases/1445806/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-and-mckesson-mck/
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG) and Immuneering (IMRX)
April 21, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1427322/analysts-offer-insights-on-healthcare-companies-passage-bio-pasg-and-immuneering-imrx/
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
April 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/21/3278411/0/en/immuneering-to-present-new-survival-data-from-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp-in-an-oral-presentation-at-the-2026-asco-annual-meeting.html
See More Immuneering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immuneering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuneering and other key companies, straight to your email.

About Immuneering

Immuneering (NASDAQ:IMRX) (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy. Immuneering also maintains discovery- and preclinical-stage programs targeting inflammatory and immuno-oncology indications. Through strategic collaborations and licensing partnerships, the company extends the application of its computational platform across multiple therapeutic areas and works alongside pharmaceutical partners to co-develop novel treatments.

Founded in 2016, Immuneering is headquartered in Cambridge, Massachusetts, and operates research facilities in the United States. After completing its initial public offering on the Nasdaq in early 2021, the company has continued to expand its computational infrastructure, diversify its pipeline through in-house research and external collaborations, and advance its mission to bring more effective, AI-driven therapies to patients worldwide.

View Immuneering Profile
Earnings Tools